Palatin Technologies, Inc.(NYSE Amex Equities : PTN)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | -0.43% | 178.00 | 0.7% | $1154.07m | |
| LLY | Eli Lilly & Co. | -0.92% | 367.00 | 1.1% | $1126.70m | |
| MRK | Merck & Co., Inc. | -0.71% | 109.05 | 0.7% | $1025.89m | |
| PFE | Pfizer Inc. | -1.02% | 50.62 | 0.9% | $981.72m | |
| ABBV | AbbVie, Inc. | -0.67% | 160.50 | 1.9% | $860.26m | |
| BMY | Bristol-Myers Squibb Co. | -0.98% | 80.08 | 1.1% | $764.15m | |
| AZN | AstraZeneca Plc | -0.57% | 67.95 | 1.0% | $356.07m | |
| HZNP | Horizon Therapeutics Plc | 2.10% | 103.00 | 5.4% | $315.71m | |
| IDXX | IDEXX Laboratories, Inc. | -1.92% | 430.74 | 3.9% | $225.57m | |
| CTLT | Catalent, Inc. | 1.46% | 53.00 | 1.9% | $216.78m | |
| GSK | GSK Plc | 0.07% | 35.06 | 0.3% | $189.88m | |
| NVS | Novartis AG | -1.34% | 88.61 | 0.2% | $183.84m | |
| NVO | Novo Nordisk A/S | -0.74% | 125.19 | 0.1% | $171.53m | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 0.00% | 220.25 | 8.0% | $161.43m | |
| RGEN | Repligen Corp. | 0.00% | 188.17 | 6.7% | $134.32m |
Company Profile
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.